Oppenheimer & Co. Inc. Buys 14,867 Shares of Savara Inc (NASDAQ:SVRA)

Oppenheimer & Co. Inc. boosted its holdings in Savara Inc (NASDAQ:SVRA) by 14.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 115,604 shares of the company’s stock after purchasing an additional 14,867 shares during the period. Oppenheimer & Co. Inc.’s holdings in Savara were worth $490,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. ProShare Advisors LLC boosted its holdings in Savara by 9.0% in the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock worth $128,000 after acquiring an additional 2,114 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Savara by 15.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock valued at $168,000 after buying an additional 4,625 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Savara by 14.9% in the second quarter. The Manufacturers Life Insurance Company now owns 41,250 shares of the company’s stock valued at $166,000 after acquiring an additional 5,335 shares in the last quarter. Principal Financial Group Inc. raised its stake in Savara by 64.4% during the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after purchasing an additional 6,973 shares during the period. Finally, CANADA LIFE ASSURANCE Co bought a new stake in shares of Savara during the first quarter valued at approximately $35,000. 87.93% of the stock is owned by institutional investors.

Savara Stock Up 6.5 %

SVRA stock opened at $3.13 on Thursday. Savara Inc has a one year low of $2.82 and a one year high of $5.70. The firm has a market cap of $537.17 million, a PE ratio of -7.23 and a beta of 1.02. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The firm’s fifty day moving average is $3.82 and its 200 day moving average is $4.16.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.11). On average, research analysts forecast that Savara Inc will post -0.45 EPS for the current year.

Wall Street Analyst Weigh In

SVRA has been the subject of several recent analyst reports. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Savara in a research report on Tuesday, October 1st. Evercore ISI reissued an “in-line” rating and set a $5.00 target price (down previously from $7.00) on shares of Savara in a research report on Wednesday, November 13th. Finally, HC Wainwright decreased their price objective on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.17.

Insider Activity at Savara

In other Savara news, Director Joseph S. Mccracken purchased 20,000 shares of Savara stock in a transaction that occurred on Tuesday, November 19th. The stock was purchased at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the transaction, the director now directly owns 210,837 shares in the company, valued at $621,969.15. This trade represents a 10.48 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 5.13% of the stock is owned by insiders.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.